RxDoctor Payments Data

Nicolas Morton-Gonzaba, MD

Internal Medicine · San Antonio, TXNPI 1407477060

Payments from drug & device makers

$955in general payments, 2019–2025

Across 45 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$264
  • Lilly USA, LLC$197
  • Boehringer Ingelheim$141
  • GSK$79
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$54
  • Sanofi-aventis U.S. LLC$53
  • plus $168 from 7 others

What the payments were for

  • Food & beverage$955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$955 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$38,528
Medicare patients
82
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide89$98,551
TrulicityDulaglutide57$62,172
JardianceEmpagliflozin58$61,582
OzempicSemaglutide44$41,714
EliquisApixaban37$30,173
RybelsusSemaglutide23$29,244
FarxigaDapagliflozin Propanediol24$24,749
RexultiBrexpiprazole13$22,708
JanuviaSitagliptin Phosphate15$21,114
LinzessLinaclotide21$16,580
XareltoRivaroxaban16$12,466
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,582
Levemir FlexpenInsulin Detemir23$3,721
Insulin Lispro Kwikpen U-100Insulin Lispro15$2,417
Rosuvastatin Calcium122$2,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$197$160,723146 claims
Novo NordiskOzempic, Rybelsus$264$70,95967 claims
Boehringer IngelheimJardiance$141$61,58258 claims
PfizerEliquis$21$30,17337 claims
MerckJanuvia$20$21,11415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →